Please login to the form below
UniQure
This page shows the latest UniQure news and features for those working in and with pharma, biotech and healthcare.
NICE publishes draft guidance not recommending CSL's haemophilia B gene therapy
CSL licensed the exclusive global rights to Hemgenix from gene therapy company uniQure in May 2021 and is now solely responsible for the further development, registration and commercialisation of the therapy.
Latest news
-
EC approves first gene therapy for adults with haemophilia B
CSL licensed the exclusive global rights to Hemgenix from gene therapy company uniQure in May 2021 and is now solely responsible for the further development, registration and commercialisation of the therapy.
-
FDA approves first gene therapy for adults with haemophilia B
Matt Kapusta, chief executive officer of uniQure, also said the approval represented a “major milestone in the field of genomic medicine and ushers in a new treatment paradigm for patients living ... CSL licensed the exclusive global rights to Hemgenix
-
FDA removes clinical hold on uniQure’s haemophilia gene therapy
In a statement, uniQure said that the patient diagnosed with HCC had ‘multiple risk factors’ associated with this type of cancer. ... UniQure added that all patients in its haemophilia clinical programme have abdominal ultrasounds performed one year
-
UK’s CMA clears Roche’s $4.3bn takeover of Spark
Athough, analysts at Jefferies have previously suggested that with a number of other companies developing gene therapies – including BioMarin, Sangamo and UniQure – that should not be considered overly dominant.
-
Roche moving closer to approval of Spark takeover; report
number of other companies developing gene therapies – including BioMarin, Sangamo and UniQure – that should not be considered overly dominant.
More from news
Approximately 13 fully matching, plus 25 partially matching documents found.
Latest Intelligence
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Gene therapy failures. The industry and Europe’s healthcare systems are wary of that magic one million threshold, thanks to the failure of the first ever gene therapy, UniQure’s Glybera. ... The success or failure of Bluebird will be closely watched
-
Bluebird Bio: on the cusp of a gene therapy revolution
success. Europe has already seen two gene therapies approved but fail commercially – UniQure’s Glybera and GSK’s Strimvelis – and so Bluebird has to learn lessons on pricing and reimbursement and ... The EMA approved the world’s first ever
-
Rare diseases: meeting the challenge
Unfortunate message. Some of these thorny problems were encapsulated in uniQure’s recent decision not to seek an extension to its five-year European marketing authorisation - which expires in October - for
-
Pharma deals in April 2015
BMS will also take a 4.9% equity stake in uniQure which will cost around $32m, with another 5% ownership scheduled before the end of the year (at 10% premium). ... UniQure also stands to receive research, development and regulatory milestones, including
-
Medius Deal Watch table for April 2015
32, 700. uniQure NV/ Bristol-Myers Squibb. R&D collaboration plus equity investment.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Therachon appoints Christian Meyer as chief medical officer
Meyer joins the biotech from uniQure B.V where he was chief medical officer and has held several similar roles for Cardoz, Symphogen, Zymenex and Novo Nordisk.
-
uniQure appoints chief executive officer
Based in the Netherlands and the US, uniQure has appointed Matthew Kapusta as its chief executive officer. ... This is an exciting time for uniQure, and I am fully committed to the company's success and the execution of our core strategic goals.
-
Basilea's Hans Christian Rohde takes up commercial role at uniQure
Will serve as gene therapy specialist's chief commercial officer. Gene therapy company uniQure has appointed Hans Christian Rohde to serve as its new chief commercial officer. ... In his new role at Netherlands-based uniQure he will be tasked with
More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Solaris Health looks at the gene therapy revolution
There has already been one notable disappointment. In 2017 uniQure pulled its gene therapy, Glybera (alipogene tiparvovec) for the rare inherited disorder lipoprotein lipase deficiency (LPLD) from Europe after 5 years,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Twist Health
Not just another healthcare communications agency. We are a collection of award-winning industry experts focusing on bringing the very best...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
